Vemlidy tackles hep B in late-stage trials
The impact of chronic hepatitis B treatment on hepatocellular carcinoma incidence was evaluated in a long-term analysis of the Gilead drug.
Read More
Tag: Vemlidy
GSK’s Dovato hits endpoints in late-stage study
In a Phase III study the drug combo was as effective in controlling HIV-1 as a Vemlidy combo.
Read More
EU approves Gilead’s hepatitis B therapy Vemlidy
Patients with chronic hepatitis B in Europe have gained the first new treatment option in nearly 10 years following the approval of Gilead’s Vemlidy.
Read More
Nine therapies put forward for EU approval
Nine therapies spanning a range of diseases have been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including three biosimilars and two diabetes drugs.
Read More
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
- Alzecure enters collaboration and with Lilly for Alzheimer’s project
- Survodutide trial data show targeted visceral and liver fat reductions
- Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
- European approval enables measles protection with CSL’s immunoglobulin Privigen
